Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-05-18 | Dec-31-17 | Dec-31-16 |
| Revenues | 2,549.4 | 2,399.8 | 1,853.7 | 1,835.9 | 1,961.0 | 1,961.0 | 1,878.6 | 1,770.1 |
| Revenue growth | 6.2% | 29.5% | 1.0% | -6.4% | 4.4% | | 6.1% | -30.4% |
| Cost of goods sold | 1,596.7 | 1,439.0 | 1,067.7 | 1,047.6 | 1,123.4 | 1,123.4 | 1,064.8 | 992.8 |
| Gross profit | 952.7 | 960.8 | 786.0 | 788.3 | 837.6 | 837.6 | 813.8 | 777.3 |
| Gross margin | 37.4% | 40.0% | 42.4% | 42.9% | 42.7% | 42.7% | 43.3% | 43.9% |
| Selling, general and administrative | 578.6 | 611.2 | 504.7 | 497.0 | 544.8 | 589.1 | 567.2 | 596.3 |
| Research and development | 48.8 | 49.7 | 48.6 | 42.2 | 44.3 | 44.3 | 46.4 | 45.0 |
| EBITA | 445.3 | 423.9 | 351.7 | 362.1 | 360.5 | 248.5 | 320.7 | 246.7 |
| EBITA margin | 17.5% | 17.7% | 19.0% | 19.7% | 18.4% | 12.7% | 17.1% | 13.9% |
| Amortization of intangibles | 120.0 | 124.0 | 119.0 | 113.0 | 112.0 | | 110.0 | 109.0 |
| EBIT | 325.3 | 299.9 | 232.7 | 249.1 | 248.5 | 248.5 | 210.7 | 137.7 |
| EBIT margin | 12.8% | 12.5% | 12.6% | 13.6% | 12.7% | 12.7% | 11.2% | 7.8% |
| Pre-tax income | 272.0 | 251.7 | 81.1 | 140.9 | -53.2 | -100.8 | -260.4 | -231.8 |
| Income taxes | 85.8 | 48.3 | 4.3 | 61.3 | 23.8 | -23.8 | -68.6 | -41.3 |
| Tax rate | 31.5% | 19.2% | 5.3% | 43.5% | | 23.6% | 26.3% | 17.8% |
| Earnings from continuing ops | 185.4 | 203.0 | 76.8 | 78.9 | -81.5 | -77.0 | -192.4 | -154.6 |
| Earnings from discontinued ops | 1.8 | 0.3 | -1.1 | 13.3 | -242.9 | -242.9 | -103.8 | 113.8 |
| Net income | 187.2 | 203.3 | 75.7 | 92.2 | -324.4 | -319.9 | -296.2 | -40.8 |
| Net margin | 7.3% | 8.5% | 4.1% | 5.0% | -16.5% | -16.3% | -15.8% | -2.3% |
| |
| Diluted EPS | $0.75 | $0.82 | $0.31 | $0.30 | ($0.28) | ($78.08) | ($0.67) | ($0.57) |
| Shares outstanding (diluted) | 245.8 | 247.9 | 249.9 | 260.1 | 288.2 | 1.0 | 286.1 | 272.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|